Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 voxelotor versus placebo in sickle cell disease
NL-OMON49079Phase 3Active, not recruiting
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of voxelotor in sickle cell disease (SCD) and anaemia (3 arms), sponsored by Global Blood Therapeutics, Inc. Primary endpoint: Hemoglobin response at Week 24. Started Feb 2018; status: active, not recruiting.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)anaemia
Beyond the preview
Go deeper on NL-OMON49079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49079.